{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:35:23Z","timestamp":1787495723945,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eclinm.2025.103261","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T13:47:58Z","timestamp":1748094478000},"page":"103261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9259-8107","authenticated-orcid":false,"given":"Kiu","family":"Tay-Teo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Meheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-6595","authenticated-orcid":false,"given":"Andr\u00e9","family":"Ilbawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-6507","authenticated-orcid":false,"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103261_bib1","series-title":"Global Oncology trends 2024: outlook to 2028","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103261_bib3","series-title":"In the eye of the storm: PD-(L)1 inhibitors weathering turbulence - challenges and opportunities as the immune checkpoint inhibitor market matures","author":"Gores","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103261_bib4","series-title":"2021 Global burden of disease study - GBD results tool","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103261_bib5","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","volume":"149","author":"Low","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2025.103261_bib7","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/S1470-2045(24)00212-2","article-title":"Interchangeability of immune checkpoint inhibitors: an urgent need for action","volume":"25","author":"Zietse","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib8","article-title":"Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending","volume":"3","author":"Goldstein","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx063","article-title":"Phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non\u2013small cell lung cancer","volume":"109","author":"Goldstein","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2025.103261_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0042-1742651","article-title":"Pembrolizumab weight based dosing \u2013 a call for policy change","volume":"43","author":"Patel","year":"2022","journal-title":"Ind J Med Paediatr Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib11","series-title":"National dose banding table \u2013 pembrolizumab 25 mg\/mL","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103261_bib12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1177\/1078155218812943","article-title":"Implications of parenteral chemotherapy dose standardisation in a tertiary oncology centre","volume":"25","author":"Finch","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.eclinm.2025.103261_bib13","first-page":"29","article-title":"Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital","volume":"8","author":"Chiumente","year":"2021","journal-title":"Glob Reg Heal Technol Assess"},{"key":"10.1016\/j.eclinm.2025.103261_bib14","series-title":"The selection and use of essential medicines: report of the WHO expert committee on selection and use of essential medicines, 2019 (including the 21st WHO model list of essential medicines and the 7th WHO model list of essential medicines for children)","year":"2019"},{"key":"10.1016\/j.eclinm.2025.103261_bib15","series-title":"WHO technical report series, No. 1035","article-title":"The selection and use of essential medicines: report of the WHO expert committee on selection and use of essential medicines, 2021 (including the 22nd WHO model list of essential medicines and the 8th WHO model list of essential medicines for children)","year":"2021"},{"key":"10.1016\/j.eclinm.2025.103261_bib16","series-title":"WHO technical report series, No. 1049","article-title":"The selection and use of essential medicines: report of the WHO expert committee on selection and use of essential medicines, 2023 (including the 23rd WHO model list of essential medicines and the 9th WHO model list of essential medicines for children)","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103261_bib17","series-title":"ESMO-magnitude of clinical benefit scale","year":"2025"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103261_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO Global Consortium Study on the availability, out-of-pocket costs , and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cllc.2024.05.002","article-title":"5-year real-world outcomes with frontline pembrolizumab monotherapy in PD-L1 expression \u226550% advanced NSCLC","volume":"25","author":"Velcheti","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.eclinm.2025.103261_bib20","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/1759-7714.15069","article-title":"Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: results from a retrospective chart review of patients with advanced\/metastatic non-small cell lung cancer in the EU5","volume":"14","author":"Slowley","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.eclinm.2025.103261_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.33868","article-title":"The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours \u2014 a real-world multicentric study from India","volume":"150","author":"Abraham","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2025.103261_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib23","article-title":"CADTH reimbursement recommendation- Pembrolizumab (Keytruda)","volume":"2","year":"2022","journal-title":"Canada J Heal Technol"},{"key":"10.1016\/j.eclinm.2025.103261_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11523-024-01087-4","article-title":"An evidence-based rationale for dose de-escalation of subcutaneous atezolizumab","volume":"19","author":"Kicken","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib26","series-title":"Japan's NHI drug price system","author":"Abe","year":"2021"},{"key":"10.1016\/j.eclinm.2025.103261_bib27","series-title":"\u4ee4\u548c7\u5e74\u5ea6\u85ac\u4fa1\u6539\u5b9a\u306b\u3064\u3044\u3066 [Regarding the FY2025 drug price revision]","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103261_bib28","first-page":"1","article-title":"Reduction of biologic pricing following biosimilar introduction: analysis across 57 countries and regions, 2012-19","volume":"19","author":"Chen","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2025.103261_bib29","first-page":"1","article-title":"Biosimilar underutilization alone does not foretell a broken biologics market","volume":"2","author":"LaMountain","year":"2024","journal-title":"Heal Aff Sch"},{"key":"10.1016\/j.eclinm.2025.103261_bib30","first-page":"902","article-title":"Shift from adalimumab originator to biosimilars in Denmark","volume":"180","author":"Jensen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103261_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41256-024-00372-z","article-title":"Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023","volume":"9","author":"Wu","year":"2024","journal-title":"Glob Heal Res Policy"},{"key":"10.1016\/j.eclinm.2025.103261_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s41669-024-00491-w","article-title":"Impact of value-driven healthcare strategies for biosimilar adoption: the Singapore story","volume":"8","author":"Tan","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.eclinm.2025.103261_bib33","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/j.annonc.2024.08.1315","article-title":"Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial","volume":"35","author":"van den Heuvel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib34","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(15)00755-2","article-title":"Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition","volume":"387","author":"Gelband","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103261_bib35","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non -small-cell lung cancer and programmed death Ligand-1 tumor proportion score >=1 % in the KEYNOTE-042 Study","volume":"41","author":"de Castro","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103261_bib36","series-title":"WHO guideline on country pharmaceutical pricing policies","year":"2020"},{"key":"10.1016\/j.eclinm.2025.103261_bib37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/19420862.2015.1107688","article-title":"Intellectual property issues of immune checkpoint inhibitors","volume":"8","author":"Storz","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.eclinm.2025.103261_bib38","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/jama.2023.25389","article-title":"Biologic patent thickets and terminal disclaimers","volume":"331","author":"Tu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103261_bib39","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10198-023-01648-w","article-title":"The impact of an \u2018evergreening\u2019 strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands","volume":"25","author":"Kirshner","year":"2024","journal-title":"Eur J Heal Econ"},{"key":"10.1016\/j.eclinm.2025.103261_bib40","series-title":"Biosimilar medicines can be interchanged","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103261_bib41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.healthpol.2022.05.018","article-title":"The analogue substitution model: introducing competition in the absence of generic substitution in Danish hospitals","volume":"126","author":"Christensen","year":"2022","journal-title":"Health Policy"},{"key":"10.1016\/j.eclinm.2025.103261_bib42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2471\/BLT.23.289714","article-title":"A National Cancer Grid pooled procurement initiative, India","volume":"101","author":"Pramesh","year":"2023","journal-title":"Bull World Heal Organ"},{"key":"10.1016\/j.eclinm.2025.103261_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6875","article-title":"Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies","volume":"2","author":"Tay-Teo","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2025.103261_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:29Z","timestamp":1760215769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"alternative-id":["S2589537025001932"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103261","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103261"}}